Delivery Order SPE2DR25D1053-SPE2DR26FT664
- Not listed
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on September 16, 2025, for the supply of Mesalamine DR 1.2 GM tablets (120 count) with a ceiling value of $10,411.70. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 17, 2025. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal military and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Mesalamine DR 1.2 GM tablets (120-count supply) on September 18, 2025, with a ceiling value of $8,208.17 and an ultimate completion date of September 19, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Mesalamine 1.2GM 120S tablets, valued at $6,421.00, with completion scheduled for October 2, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with the Defense Logistics Agency. The delivery will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120-count units) under a firm fixed-price contract valued at $3,199.95. The award was issued on August 22, 2025, with an ultimate completion date of August 25, 2025, and represents a non-set-aside competitive award. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Mesalamine DR 1.2 GM tablets (120 count) with a ceiling value of $1,924.72 under a firm fixed-price contract structure. This competitively awarded, non-set-aside delivery order was executed on April 30, 2025, with an ultimate completion date of May 1, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Mesalamine DR 1.2 GM tablets (120-count units) with a ceiling value of $14,323.16. This firm fixed-price delivery order, which is expected to be completed by August 6, 2025, represents a non-competitive set-aside and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120-count units) under a firm fixed-price contract valued at $3,249.24. The order, issued on July 1, 2025, with an ultimate completion date of July 2, 2025, represents a non-competitive set-aside delivery order for this pharmaceutical product. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving...
- The Defense Logistics Agency awarded a delivery order valued at $3,334.85 to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $2,170.31 to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120 count) on June 18, 2025, with completion scheduled for June 20, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mesalamine 800 mg delayed-release tablets (180-count) under a firm fixed-price contract. The order, valued at $40,028.47, is scheduled for completion by April 28, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation, reflecting open competition among qualified...
- SPE2DR25D1053Indefinite Delivery Contract
- SPE2DR25D1053-SPE2DR26FT664Delivery Order
AmerisourceBergen Drug Corp has been awarded a delivery order valued at $3,543.41 by the Defense Logistics Agency to supply Mesalamine DR 1.2 GM tablets (120-count units). The contract, awarded on November 6, 2025, with completion scheduled for November 7, 2025, utilizes a firm fixed-price delivery order structure with no set-aside designation, indicating competitive award. The pharmaceutical products will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and serves as a major federal healthcare supplier. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This comprehensive prime vendor contract enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally, serving customers including the Defense Health Agency and U.S. Coast Guard. The company's federal contract portfolio demonstrates its established capability to fulfill diverse pharmaceutical procurement requirements across multiple therapeutic domains through competitively awarded vehicles.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 11/6/25 |